Retraction Watch

Tracking retractions as a window into the scientific process

Cancer-anorexia paper retracted for “unacceptable” duplication

with 2 comments

doveDrug Design, Development and Therapy has retracted a 2013 paper by a group from Italy for duplication.

The retraction notice for the paper, “Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome,” fairly bristles with indignation:

The Editor-in-Chief, Dr Pilch, of Drug Design, Development and Therapy has been alerted to unacceptable levels of duplication between a previously published paper: Macciò A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin. Phar­macotherapy 2012 13(17) 2453–2472 and one published subsequently in Drug Design, Development and Therapy: Mantovani G, Madeddu C, Macciò A. Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Drug Design, Development and Therapy 2013:7 645–656.

Of course, duplication happens.  But we wonder if this might have been avoidable with a little more work on the part of the folks at Dove. Then again, right on this now-retracted article’s page is a testimonial from a happy author:

“I was impressed at the rapidity of publication from submission to final acceptance.” Dr Edwin Thrower, PhD, Yale University.

Comments
  • Paolo D. December 4, 2013 at 3:17 am

    “Unacceptable levels of duplication”. Does this mean there are “acceptable levels”?

  • CH December 5, 2013 at 5:55 am

    So much indignation, the EiC doesn’t even mention in the body of the retraction notice that the article has been retracted…

  • Post a comment

    Threaded commenting powered by interconnect/it code.